Savara Inc (SVRA):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Savara Inc (SVRA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C9832)・商品コード:DATA904C9832
・発行会社(調査会社):GlobalData
・発行日:2018年11月
・ページ数:51
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥27,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥54,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥81,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Savara Inc (Savara) formerly Mast Therapeutics Inc is a clinical stage biopharmaceutical company, which develops therapies for the treatment of rare respiratory diseases, including cystic fibrosis (CF), and pulmonary alveolar proteinosis (PAP). The company’s lead product candidates include Molgradex, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of treatment of PAP; and AeroVanc, an inhaled formulation of vancomycin for the treatment of CF. Its development pipeline also includes Aironite, a sodium nitrite solution for intermittent inhalation for the treatment of heart failure. The company has subsidiaries in the US and Denmark. Savara is headquartered in Austin, Texas, the US.

Savara Inc (SVRA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Savara Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Savara Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Savara Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Savara Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Savara Inc, Medical Devices Deals, 2012 to YTD 2018 10
Savara Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Savara Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Savara Acquires Certain Assets and Rights from Cardeas Pharma 13
Venture Financing 14
Savara Pharma Raises USD20 Million in Series C Financing Round 14
Savara Pharmaceuticals Secures USD18.54 Million in Venture Funding 15
Savara Pharma Raises Additional USD5.5 Million in Financing Round 16
Savara Pharma Raises USD4.5 Million in Financing Round 17
Savara Pharma Raises US$14 Million In Series B Financing 18
Partnerships 19
Aires Pharma Enters into Agreement with University of Pittsburgh 19
Serendex Pharma Enters into Agreement with CMC Biologics For Factor VII 20
Merger 21
Mast Therapeutics Merges with Savara 21
Licensing Agreements 23
NobelPharma Enters into Licensing Agreement with Savara 23
NobelPharma Enters into Licensing Agreement with Serendex Pharma 24
Equity Offering 25
Savara Prices Public Offering of Shares for USD48.9 Million 25
Savara Prices Public Offering of Shares for USD47.3 Million 26
Savara Raises USD42.9 Million in Public Offering of Shares 28
Savara to Raise up to USD18 Million in Public Offering of Shares 29
Savara Raises USD8 Million in Public Offering of Shares and Warrants 30
Serendex Pharma Raises USD12.7 Million Rights Offering of Shares 31
Savara Raises USD21 Million in Public Offering of Shares and Warrants 33
Savara Raises USD0.9 Million in Public Offering of Shares up on Exercise of Warrants 34
Serendex Pharma Completes IPO for USD11 Million 35
Savara Raises USD30 Million in Public Offering of Shares 37
Acquisition 38
Savara Pharma Acquires Serendex Pharma 38
Mast Therapeutics Completes Acquisition Of Aires Pharma 39
Savara Inc – Key Competitors 40
Savara Inc – Key Employees 41
Savara Inc – Locations And Subsidiaries 42
Head Office 42
Other Locations & Subsidiaries 42
Recent Developments 43
Financial Announcements 43
May 09, 2018: Savara Reports First Quarter 2018 Financial Results and Provides Business Update 43
Mar 14, 2018: Savara Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update 45
Nov 08, 2017: Savara Reports Third Quarter 2017 Financial Results and Provides Business Update 47
Aug 09, 2017: Savara Reports Second Quarter 2017 Financial Results and Provides Business Update 48
Product News 49
03/06/2017: Mast Therapeutics Announces Clinical Study Of AIR001 For The Treatment Of Chronic Infection In Cystic Fibrosis Patients 49
Clinical Trials 50
May 10, 2017: Savara Announces Expedited U.S. Molgradex Development Strategy 50
Appendix 51
Methodology 51
About GlobalData 51
Contact Us 51
Disclaimer 51

List of Tables
Savara Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Savara Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Savara Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Savara Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Savara Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Savara Inc, Medical Devices Deals, 2012 to YTD 2018 10
Savara Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Savara Acquires Certain Assets and Rights from Cardeas Pharma 13
Savara Pharma Raises USD20 Million in Series C Financing Round 14
Savara Pharmaceuticals Secures USD18.54 Million in Venture Funding 15
Savara Pharma Raises Additional USD5.5 Million in Financing Round 16
Savara Pharma Raises USD4.5 Million in Financing Round 17
Savara Pharma Raises US$14 Million In Series B Financing 18
Aires Pharma Enters into Agreement with University of Pittsburgh 19
Serendex Pharma Enters into Agreement with CMC Biologics For Factor VII 20
Mast Therapeutics Merges with Savara 21
NobelPharma Enters into Licensing Agreement with Savara 23
NobelPharma Enters into Licensing Agreement with Serendex Pharma 24
Savara Prices Public Offering of Shares for USD48.9 Million 25
Savara Prices Public Offering of Shares for USD47.3 Million 26
Savara Raises USD42.9 Million in Public Offering of Shares 28
Savara to Raise up to USD18 Million in Public Offering of Shares 29
Savara Raises USD8 Million in Public Offering of Shares and Warrants 30
Serendex Pharma Raises USD12.7 Million Rights Offering of Shares 31
Savara Raises USD21 Million in Public Offering of Shares and Warrants 33
Savara Raises USD0.9 Million in Public Offering of Shares up on Exercise of Warrants 34
Serendex Pharma Completes IPO for USD11 Million 35
Savara Raises USD30 Million in Public Offering of Shares 37
Savara Pharma Acquires Serendex Pharma 38
Mast Therapeutics Completes Acquisition Of Aires Pharma 39
Savara Inc, Key Competitors 40
Savara Inc, Key Employees 41
Savara Inc, Subsidiaries 42

List of Figures
Savara Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Savara Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Savara Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Savara Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Savara Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Savara Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Savara Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Savara Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Savara Inc, Medical Devices Deals, 2012 to YTD 2018 10

★調査レポート[Savara Inc (SVRA):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C9832)販売に関する免責事項を必ずご確認ください。
★調査レポート[Savara Inc (SVRA):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆